Copyright © 2008 Elsevier Inc. All rights reserved.
Clinical Investigation
Impact of [18F] Fluorodeoxyglucose Positron Emission Tomography on Staging and Management of Early-Stage Follicular Non-Hodgkin Lymphoma
che/MiamiImageURL/B6T7X-456FCPG-9-N/0?wchp=dGLzVzz-zSkWW" class="charImg" alt="image" title="image" height="15" width="47">: Eighty and 77 eligible patients comprised the PET and non-PET groups, respectively. The PET-selected patients had significantly less weight loss; 73%and 49%of the PET and non-PET patients, respectively, received chemotherapy. The median survival was 31 months for PET patients and 16 months for non-PET patients. Mortality from NSCLC and other causes in the first year was 17%and 8%for PET patients and 32%and 4%for non-PET patients, respectively. The hazard ratio for NSCLC mortality for PET vs. non-PET patients was 0.49 (p = 0.0016) on unifactorial analysis and was 0.55 (p = 0.0075) after adjusting for chemotherapy, which significantly improved survival.
che/MiamiImageURL/B6T7X-456FCPG-9-P/0?wchp=dGLzVzz-zSkWW" class="charImg" alt="image" title="image" height="15" width="72">: Patients selected for RRT after PET have lower early cancer mortality than those selected using conventional imaging.
View More Related Articles |
Impact of [18F] Fluorodeoxyglucose Positron Emission Tomography on Staging and Management of Early-Stage Follicular Non-Hodgkin Lymphoma